|
|
Zhaosheng Lin
Head of Biomarkers
Pfizer
 Nadine Cohen Head of Pharmacogenomics
Johnson & Johnson
 Mitchell B. Friedman Director of Toxicology
Takeda Global R&D
 Malcolm Mitchell Medical Director, Clinical Pharmacology
Eli Lilly
 Dr Russell Weiner Group Director
Bristol-Myers Squibb
|
Conference:
Pre-conference workshop
19 Oct 9am - 5pm
Day 1
20 Oct 8.30am - 5:30pm
Day 2
21 Oct 8.30am - 5:30pm
Post-conference workshop
22 Oct 9am - 5pm
Venue: Boston, MA, United States
› Email a friend
› Add this to my calendar
|
|
|
 Dr Johan Luthman,
Vice President Neuroscience & Ophthalmology Research & Development, Franchise Integrator Merck Ltd Johan Luthman is vice president and franchise integrator, Neuroscience & Ophthalmology Research & Development, at Merck Research Laboratories (MRL). In this role, he is responsible for overseeing late research and early development activities within the franchise, with an emphasis on the pathway to proof of concept trials and supported biomarkers. Dr. Luthman joined Merck in 2009.
Prior to his time at Merck, Dr. Luthman served as Therapy Area head of Neurology, Immunology & Inflammation Research, and later head of PoC strategy in Neurology at MerckSerono, a subsidiary of Merck KgaA. He joined Serono Pharmaceuticals International SA in 2005 as head of neuroscience and immunology research. Dr. Luthman began his pharmaceutical career in 1991 as a research scientist at Astra Arcus AB. After the formation of AstraZeneca, he worked as director of Bioscience, followed by an appointment as director of translational science in Neurology and Analgesia
Dr. Luthman studied medicine and dentistry at Karolinska Institute in Stockholm and continued with postgraduate studies in neuroscience, which led to a doctorate in neurobiology. He received an honorary professorship in pharmacology in 2002 from the University of Chile in Santiago.
Appearing: Day Two, Thursday 21 October 2010 9am The Changing R&D Process: the Need to Move From a Linear Model to Highly Interactive Drug Discovery and Development
- The changing R&D process; the need to move from a linear model to highly interactive drug discovery and development
- Organizational models to support the interactive R&D concept.
- The need to balance the key drivers, medical need and innovation, with increased success rate
- Introduce novel methodologies, while improving established ways of working
- Time to assess return on investment for Proof of Concept and biomarker strategies
Dr Johan Luthman, Vice President Neuroscience & Ophthalmology Research & Development, Franchise Integrator,
Merck Ltd |
|
|
|
|
|
Reserve an exhibition stand at the Exploratory Clinical Development World Americas exhibition - book early to ensure optimum stand placement!
| |
Reserve a stand
For details contact
Claire Conway on +44 (0) 207 608 7058 |
|
|
|
|
|
|
|
|
|
